INFORME DE BÚSQUEDA DE PATENTES	
N° de solicitud: 16147105	
CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los boléanos utilizados)**	
Palabras clave utilizadas	Injectable formulations; Ethanol; Sesame oil; Immune Response Modifier.
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA	**CIP:** A61K31/4178; A61K9/16
	CPC (Opcional):

DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc…)

Informes/Base de datos	N° de solicitud/ Autor*	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (con indicación, si procede, de las partes relevantes)	Categoría especiales de los documentos citados**
STN, PATBASE; ORBIT; ESPACENET y USPTO	US2013230578	05/Septiembre/2013	1 a 13 NIVEL INVENTIVO	Y
	WO2011112669	15/Septiembre/2011	1 a 13 NIVEL INVENTIVO	Y

** Categorías especiales de documentos citados:

"A" documento que define el estado general de la técnica no considerado como particularmente relevante. **"E"** solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. **"P"** documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.	**"X"** documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. **"Y"** documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.

Literatura no patente *Se incluye entre otros, toda la referencia de la literatura no patente.	--
Fecha del reporte de búsqueda:	27/02/2019

PATBASE





ORBIT



ESPACENET

Documents cited:	**Search**	[E]↗ WO2016019232 (VASILAKOS JOHN [US], et al) [E] 1-30 * examples 1-3 * * pages 32-33, paragraph Materials *;
		[A]↗ WO2005001022 (3M INNOVATIVE PROPERTIES CO [US], et al) [A] 1-30 * claims 1-15,18,20-22,24,27 *;
		[A]↗ WO2006074045 (3M INNOVATIVE PROPERTIES CO [US], et al) [A] 1-30 * abstract *
		[XP] - M. SINGH ET AL, "Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation", THE JOURNAL OF IMMUNOLOGY, US, (20140924), vol. 193, no. 9, doi:10.4049/jimmunol.1401160, ISSN 0022-1767, pages 4722 - 4731, XP055290072 [XP] 1-30 * abstract * * page 4723, column I, paragraphs 3M-052 and its vehicle * **DOI:** ↗ http://dx.doi.org/10.4049/jimmunol.1401160
		[A] - DMITRI SMIRNOV ET AL, "Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 29, no. 33, doi:10.1016/J.VACCINE.2011.05.061, ISSN 0264-410X, (20110519), pages 5434 - 5442, (20110525), XP028240658 [A] 1-30 * abstract * * page 5436, paragraphs Formulation of M-052 in liposomes * **DOI:** ↗ http://dx.doi.org/10.1016/j.vaccine.2011.05.061
	International search	[Y]↗ US2013230578 (WIGHTMAN PAUL D [US]);
		[Y]↗ WO2011112669 (CENTOCOR ORTHO BIOTECH INC [US], et al);

2. Citations and explanations:

Claims 1-3 lack an inventive step under PCT Article 33(3) as being obvious over US 2013/0230578 A1 (Wightman) in view of WO 2011/112669 A1 by Hill et al. (hereinafter 'Hill').

Regarding claim 1, Wightman teaches a pharmaceutical formulation suitable for injection, comprising: sesame oil (para [0056]), and an immune response modifier compound of formula (structure shown in the claim), wherein: X is alkylene having up to 6 carbon atoms optionally interrupted or terminated by -O- (para 0005] and claim 1); R2 is hydrogen (para [0005] and claim 1); Y is -C(O)- (para [0005] and claim 1); R1 is a linear aliphatic group having 11-23 carbon atoms (para [0005] and claim 1); and R is hydrogen (para [0005] and claim 1); or a pharmaceutically acceptable salt thereof (para [0005] and claim 1). Wightman does not teach ethanol, but does teach the formulation containing an immune response modifier (para 0005] and claim 1). Hill teaches an injectable formulation (pg 23, ln 21 to pg 24, ln 15) that uses sesame oil and ethanol as reduced viscosity vehicle (pg. 9 in 2-8 and in 11-15; pg 19-20, Example 1; claims 1-3). It woud have been obvious to one of ordinary skill in the art to combine the compounds of Wightman and the excipients of Hill to make a formulation containing both sesame oil and ethanol as a reduced viscosity vehicle, in order to increase the bioavailability of the immune response modifier composition and to reduce viscosity of the material during injection, because both Wightman and Hill teach formulations that can be administered by injection to a subject.

Regarding claim 2, Wightman teaches the formulation of claim 1 containing sesame oil and the immune response modifier, but does not teach the formulation of claim 1, wherein the ethanol is present in a concentration of from about 1 wt-% to about 9 wt-%. Hill teaches formulations wherein sesame oil and ethanol are present in a concentration of from 1 wt-% to about 9 wt-% (pg. 13 ln 6-9; pg. 18 ln 12-14; pg. 19 in 30-33; pg. 20 Table 3; claims 2-5). It woud have been obvious to one of ordinary skill in the art to combine the compounds of Wightman and the excipients of Hill to make a formulation containing both sesame oil and ethanol as a reduced viscosity vehicle, in order to increase the bioavailability of the immune response modifier composition and to reduce viscosity of the material during injection, because both Wightman and Hill teach formulations that can be administered by injection to a subject.

Regarding claim 3, Wightman teaches the formulation of claim 1 containing sesame oil and the immune response modifier, but does not teach the formulation of claim 1, wherein the ethanol is present in a concentration of from about 1 wt-% to about 9 wt-%. Hill teaches formulations wherein the ethanol is present in a concentration of from 1 wt-% to about 9 wt-% (pg. 18 ln 12-14; pg. 19 in 30-33; pg. 21 Table 4; claims 2-5). It woud have been obvious to one of ordinary skill in the art to combine the compounds of Wightman and the teachings of Hill to make a formulation containing both sesame oil and ethanol as a reduced viscosity vehicle, in order to increase the bioavailability of the immune response modifier composition and to reduce viscosity of the material during injection, because both Wightman and Hill teach formulations that can be administered by injection to a subject.

uspto

refere 1/3

Help MyUSPTO

Public Patent Application Information Retrieval

Patent eBusiness

- Electronic Filing
- Patent Application Information (PAIR)
- Patent Ownership
- Fees
- Supplemental Resources & Support

Patent Information

Patent Guidance and General Info
- Codes, Rules & Manuals
- Employee & Office Directories
- Resources & Public Notices

Patent Searches

Patent Official Gazette
- Search Patents & Applications
- Search Biological Sequences
- Copies, Products & Services

Other

Copyrights
Trademarks
Policy & Law
Reports

Patent Application Information Retrieval

Global Dossier | Order Certified Application As Filed | Order Certified File Wrapper | View Order List

15/032,773 SESAME OIL BASED INJECTION FORMULATIONS 200242-US-PCT

Select New Case | Application Data | Transaction History | Image File Wrapper | Continuity Data | Published Documents | Address & Attorney/Agent | Assignments | Display References

This application is officially maintained in electronic form. To View: Click the desired Document Description. To Download and Print: Check the desired document(s) and click Start Download.

Available Documents

Mail Room Date	Document Code	Document Description	Document Category	Page Count	PDF
08-02-2018	ELC.	Response to Election / Restriction Filed	PROSECUTION	1	
08-02-2018	WFEE	Fee Worksheet (SB06)	PROSECUTION	2	
08-02-2018	N417	EFS Acknowledgment Receipt	PROSECUTION	2	
05-03-2018	CTRS	Requirement for Restriction/Election	PROSECUTION	6	
12-09-2016	N572	Response - Re: Informal Power of Attorney (PTOL-308)	PROSECUTION	1	
12-06-2016	PA..	Power of Attorney	PROSECUTION	1	
12-06-2016	OATH	Oath or Declaration filed	PROSECUTION	5	
12-06-2016	WFEE	Fee Worksheet (SB06)	PROSECUTION	2	
12-06-2016	N417	EFS Acknowledgment Receipt	PROSECUTION	2	

STN

STN

https://www.stn.org/stn/#page=project&projectId=null

STN® Projects Working On – Untitled4 ▼ Welcome, Nelson Velasco Layout ▼ Settings STN Help ▼ Contact Us Sign Out

CAplus, REGISTRY, MARPAT, MEDLINE

Enter your query...

Submit

QUERIES (22) STRUCTURES (0) SAVED (0)

Expand All | Collapse All

	CAplus	REGISTRY	MARPAT	MEDLINE
		38.681	509	1.865
L21 Immune Response Modifier (CAplus, REGISTRY, MARPAT, MEDLINE)	412	7.683	115	417

L22 COUNTS RESULTS

CAplus (5) REGISTRY (129) MARPAT (5) MEDLINE (1)

Get Substances View: Hit Sort by: Accession Number Display: 25

1. Patent 2017 **Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof**

Le Hir de Fallois, Loic Patrick • Meng, Charles Q. • Cady, Susan Mancini • Cheifetz, Peter • Galeska, Izabela
Merial Inc., United States (US)
U.S. Pat. Appl. Publ., pp. 92 *In English*
2017:1371530 (DN 167:322558)

Substance Indexing

2021230-37-3P
2126931-17-5P

Notes: antiparasitic isoxazoline compds., long-acting **injectable** **formulations** comprising them, methods and uses thereof

Roles: Biological Study (BIOL),Preparation (PREP),Synthetic Preparation (SPN),Therapeutic Use (THU),Uses (USES)

64-17-5, **Ethanol**

Notes: antiparasitic isoxazoline compds., long-acting **injectable** **formulations** comprising them, methods and uses thereof

Roles: Biological Study (BIOL),Therapeutic Use (THU),Uses (USES)

2222236-38-4

Notes: antiparasitic isoxazoline compds., long-acting **injectable** **formulations** comprising them, methods and uses thereof

Roles: Catalyst Use (CAT),Uses (USES)

1190856-14-4P
1190858-98-0P
2138407-75-5P
More

Notes: antiparasitic isoxazoline compds., long-acting **injectable** **formulations** comprising them, methods and uses thereof

Roles: Preparation (PREP),Reactant (RCT),Reactant or Reagent (RACT),Synthetic Preparation (SPN)

Selected: 0 | Total: 0

CAplus℠ Copyright © 2019 ACS on STN

About STN Terms & Conditions

Copyright © 2019 American Chemical Society. All Rights Reserved.

ESP 10:59 27/02/2019